(Q62813487)
Statements
A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation (English)
0 references
25 April 2018
0 references
December 2020
0 references
130
0 references
6 year
0 references